Category Archives: Platelet Rich Plasma Injections


PRP Under Eye Treatment: What You Should Know – The Herald-News

Tired of looking in the mirror and seeing those unwanted signs of aging around your eyes? Forget going under the knife theres a new option that harnesses the power of your own body to achieve a brighter, more youthful appearance.

Platelet-Rich Plasma (PRP) injections are a revolutionary treatment offered at Eterna MedSpa & Laser Vein Center that can tackle a multitude of under-eye concerns.

The procedure uses a clients own blood plasma to tighten the skin and reduce wrinkles. How?

During the treatment, a small amount of blood is drawn and then placed in a centrifuge where it is spun at high speeds so the plasma rises to the top. The plasma is then drawn out into a syringe and injected in the under eye area.

The plasma contains proteins which strengthen and volumize the skin. In the under-eye area, rejuvenation occurs, stimulating the natural production of collagen, elastin, and hyaluronic acid.

The benefits of Platelet-Rich Plasma extend beyond just wrinkle reduction.

PRP helps with dark circles, puffiness, and shallowness under the eyes, said Kathe Malinowski, lead esthetician and Marketing Manager for Eterna MedSpa & Laser Vein Center. It also minimizes crepey skin under the eye area.

The results of the injections can last anywhere from six months to a year, depending on your individual age and skin condition.

Wondering if Platelet-Rich Plasma therapy is the right choice for you? Eterna MedSpa offers complimentary consultations with a nurse where you can discuss your goals and get a personalized treatment plan.

Dont wait any longer to achieve the beautiful, youthful eyes you deserve explore the power of PRP at Eterna MedSpa & Laser Vein Center.

For more information, please contact:

Eterna MedSpa & Laser Vein Center : 217 Vertin Boulevard : Shorewood, IL 60404 : 815.254.8888 : https://www.eternalaser.com/

[SPONSORED] Eterna MedSpa offers products that rejuvenate Jessica Knowles of Eterna MedSpa discusses the importance of skincare products. Injectables and other procedures provided by Eterna MedSpa will only take patients so far. Regular skin care is necessary to keep your skin looking smooth and youthful.

Original post:
PRP Under Eye Treatment: What You Should Know - The Herald-News

Stem Cell and Platelet Rich Plasma Alopecia Therapies Market Analysis and Future Outlook by 2030 – openPR

The global stem cell and platelet rich plasma alopecia therapies market is expected to grow at a significant CAGR during the forecast period. Increased need for accurate and rapid alopecia treatment, as well as breakthroughs in platelet rich plasma and stem cell therapies that have transformed diagnostic technology, which is expected to drive the market forward. Furthermore, the global market is likely to be driven by an increase in awareness of platelet rich plasma therapies and stem cell therapies over the forecast period.

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/stem-cell-and-platelet-rich-plasma-alopecia-therapies-market

In the last few years, increased awareness has fueled demand for platelet rich plasma therapy and stem cell therapy in developing countries like Japan, India, Brazil, and Russia, as well as developed regions like North America and Europe. Furthermore, private actors are actively marketing the benefits of stem cell therapy in the treatment of alopecia around the globe. The global stem cell and platelet rich plasma alopecia therapies market is expected to grow as the incidence of autoimmune hair loss disorders such as alopecia rises. However, the global market for stem cell and platelet rich plasma alopecia therapies is anticipated to be hampered by a lack of therapy approval and the high cost of alopecia treatment.

The global market has been divided into platelet rich plasma therapies and stem cell therapy based on treatment. Owing to the therapies' efficiency in the treatment of several forms of alopecia, the platelet rich plasma therapies sector had a substantial market share. Platelet-rich plasma therapies have changed alopecia treatment by lowering expenses, lengthening treatment times, and speeding up recovery time for patients. The bone marrow and adipose stem cell treatment segments have been separated.

Global Stem Cell and Platelet Rich Plasma Alopecia Therapies Market by Segments

By Treatment

Platelet Rich Plasma Therapies Stem Cell Therapy

By End-User

Hospitals Dermatology Clinics Others

A full report of Stem Cell and Platelet Rich Plasma Alopecia Therapies Market is available at: https://www.omrglobal.com/industry-reports/stem-cell-and-platelet-rich-plasma-alopecia-therapies-market

Stem Cell and Platelet Rich Plasma Alopecia Therapies Market- Segment by Region

North America

United States Canada

Europe

Germany United Kingdom France Spain Italy Rest of Europe

Asia-Pacific

China Japan India Rest of Asia-Pacific

Rest of the World

Middle East & Africa Latin America

Company Profiles

Stemcell technologies Inc. Myungmoon Bio Co., Ltd. RepliCel Life Sciences Histogen, Inc. Glofinn Oy.

Reasons to Buying From us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors. 2. More than 120 countries are for analysis. 3. Over 100+ paid data sources mined for investigation. 4. Our expert research analysts answer all your questions before and after purchasing your report.

Visit more report at

https://www.linkedin.com/pulse/scaffold-technology-market-size-trends-latest-arti-vishwakarma-mlsof/

https://www.linkedin.com/pulse/aesthetic-threads-market-increasing-demand-growth-2031-vishwakarma-pyg5f

Media Contact:

Contact Person: Mr. Anurag Tiwari Email: anurag@omrglobal.com Contact no: +91 780-304-0404 Company Name: Orion Market Research

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.

This release was published on openPR.

Go here to read the rest:
Stem Cell and Platelet Rich Plasma Alopecia Therapies Market Analysis and Future Outlook by 2030 - openPR

Vampire Breast Lift 101: Everything to Know About the Trending Treatment – NewBeauty Magazine

By now you must have heard of the Vampire Facial which was first popularized in 2013 when Kim Kardashian took a now infamous bloody selfie. Just like the Vampire Facial, the Vampire Breast Lift utilizes platelet-rich plasma (PRP) derived from a persons own blood. The Vampire Breast Lift involves injections of PRP in the breasts to enhance fullness and lift for a quick cleavage boost.

Developed by Fairhope, AL, dermatologist Charles Runels, MD, the procedure involves drawing blood, isolating platelets containing growth factors, and combining them with hyaluronic acid fillers. Injecting this cocktail directly into the breasts can address concerns like inverted nipples, sagging, stretch marks and lack of perkiness.

Huntington Beach, CA, plastic surgeonPeter Newen, MD says that PRP injections may improve skin quality, but dont expect a lift. PRP injections may achieve some skin improvement but claims such as increased fatty tissue volume and lifting will not be observable, says Dr. Newen.

Although patients may see a temporary improvement, the results do not compare to a traditional breast lift. This should not be compared with a surgical breast lift or augmentation, in which there is a clear, long-lasting improvement.Adding PRP to the breasts can improve theskin, but it wont make a noticeable difference in breast volume or perkiness, he adds.

Dr. Runels claims that the effects of the Vampire Breast Lift may last one to two years, although these assertions lack independent verification. Grand Rapids, MI, plastic surgeonBradley Bengtson, MDexpresses concerns about the lack of data and clinical studies supporting the procedures safety and efficacy. Candidates for the Vampire Breast Lift should consult with a qualified medical professional to assess suitability and potential risks. The concerns I have with this procedureare that it tends to be performed by non-core physicians and nonsurgical doctors. There is absolutely no data about it yet, nor have there been any studies or findings on either the benefits or clinical risks associated with it, says Dr. Bengtson.

The procedure, which reportedly takes just 15 minutes, typically ranges in cost from $1,500 to $2,000. However, the exact price may vary depending on factors such as practice location and the expertise of the administering physician.

There are minimal risks, including potential bruising and swelling that typically resolve within a few days. It is essential for individuals considering this treatment to consult with board-certified providers.

While the procedure is generally deemed safe, Dr. Bengtson highlights the lack of conclusive evidence regarding long-term safety, particularly in relation to its potential impact on breast health. The breast is a cancer-prone organ, and with one in eight women in the U.S. developing breast cancer, you must wonder, what effect do these injections have on an established cancer? We dont have an answer to that yet, he cautions.

As of now, there is no FDA approval specifically for this procedure. Patients considering this treatment should thoroughly discuss potential side effects and concerns with their healthcare provider before proceeding.

Read more from the original source:
Vampire Breast Lift 101: Everything to Know About the Trending Treatment - NewBeauty Magazine

Dr. Tsambarlis on platelet-rich plasma and shock wave therapy for erectile dysfunction – Urology Times

In this video, Peter N. Tsambarlis, MD, discusses regenerative therapies for erectile dysfunction. Tsambarlis is a urologist with Northwestern Medicine in Chicago, Illinois.

The 2 main regenerative therapies are platelet-rich plasma [PRP] and shock wave therapy. But regenerative therapies is a much bigger group than that; it includes things like stem cell therapy, there are some studies with amniotics, but the 2 that are getting the most energy and the most momentum are PRP and shock wave therapy.

These are extremely popular. Obviously, we practice in Chicago, which is a really big city, and you have a subset of people who do a ton of research, by the looser definition, certainly, and want to know more about these therapies. They usually come in with a specific goal, in my experience. "I want to know about shock wave." "I want to know about PRP and if it's good for me." I try to cater the response to who it is. For example, I don't think there's anyone for whom we have good data that PRP is efficacious. But we know it's safe. But those are 2 important but very different things. Just because something is safe doesn't mean it's the best treatment option. There are just no good data that say that this is going to work for erectile dysfunction. I think that's what we want to focus on here. But certainly, there are wonderful data for PRP in the orthopedic literature. But we're not seeing it in erectile dysfunction, and even less so in things like Peyronie disease, which fall under the sexual health umbrella, but in reality are not what people are coming in for on a regular basis in my clinic. Now, the shock wave, on the other hand is really different. Shock wave has some emerging data that are getting stronger and stronger. It may not be a perfect therapy right now for everybody. And as we start to cater, who are the best candidates? What are the appropriate settings? What are the best machines? We're finding out that there are a subset of ED patients who are benefiting from shock wave, and it is more of a call to research. How do we identify the proper protocol? How do we optimize patient selection to get these things to work? But since we don't exactly know, I don't think it's wrong to offer it in patients for whom you have a reasonable expectation of success, but you have to be really transparent about it. You can't promise the world if you don't have the world to give.

PRP is not ready to be utilized as a treatment. It can be utilized as an experimental, but do it in the setting of an experiment, of a trial, something that's controlled. Shock wave is way further down the road, in my opinion. I think it's a reasonable option, as long as you're transparent about it. But you still have to make sure as a patient that you're getting that therapy from somewhere that has, for example, focal shock waves. A lot of these outside clinics are using radial waves, and we have excellent trade of them that is not useful. Not all shock wave is created equal, and it underscores the importance of going somewhere that you can trust. I think even if this is offered as a therapy, which maybe is associated with some sort of reimbursement, it needs to be somewhere where the data can be tracked. I think there's kind of a gray area - are we at the point where this is ready for primetime and this can be offered? "I'm not sure," is the answer. But there are enough encouraging data that say it is definitely safe and might be efficacious, that I think at least if we're tracking the data, we can provide benefit to some people and then utilize what we learn to help a larger portion.

This transcription was edited for clarity.

Go here to see the original:
Dr. Tsambarlis on platelet-rich plasma and shock wave therapy for erectile dysfunction - Urology Times

Platelet-Rich Plasma Injections | What It’s Like Getting PRP Injections Into The Knee as a Skier – SnowBrains

In November 2021, I hiked up and skied Little Chute at Alta, UT.

When skiing down my knee swelled up and I could only bend it 90.

After arriving home the swelling went down.

This happened on a daily repeat cycle until February 2022 when the pain upon skiing became so intense I had to stop skiing altogether.

I talked to my surgeon.

He quickly diagnosed me with osteoarthritis caused by my knee surgery in 2015 to replace my ACL.

I had also vaporized my meniscus and ripped off a square centimeter of cartilage on the end of my femur resulting in a microfracture surgery (performed at the same time as my ACL replacement).

The first course of action was a Non-Steroidal Anti-Inflammatory Drug (NSAID) regimen (ibuprofen, etc).

That didnt work.

In February 2022, I had my first Platelet-Rich Plasma (PRP) injection.

I coupled the injection with 4 weeks off from skiing and physical therapy.

I returned to skiing in March 2022 and had a decent March, April, and May 2022.

I surfed great waves with no issues in the Maldives all of June and July (surfing is not hard on knees).

I returned to snow in August 2022 in Patagonia and on day #1 my knee swelled up and was painful again.

I was only able to ski 22 out of 60 days that summer

I went back in for another PRP injection in October.

This time it worked.

I had a strong 2022/23 ski season with record snowfall across the west and I skied 305 out of 365 days that year without issue, swelling, nor pain.

Since then, Ive officially drunk the Kool-Aid.

I found a doctor who will do PRP injections for $450 a pop and Im doing them every 3 months.

This week, I got my 5th PRP injection in the lateral compartment of my left knee (where there is no meniscus and no cartilage).

I plan on continuing with these PRP injections indefinitely.

In general, its advised to take it easy for a day or two after the injection.

I sometimes experience swelling for 24 hours after the PRP injection.

I believe that these injections are working for me and hopefully, theyll help me put off getting a knee replacement until Im at least 55.

Fingers crossed.

Im 45 years old, 61, 165lbs and Ive been skiing full time since I was 22 and Ive skied year round the last 13 years.

PRP treatment is not yet fully proven by science and therefore, health insurance generally wont cover it.

I also do a lot of physical therapy (building up the muscles in my legs) and I have a custom-made DonJoy knee brace that I wear anytime I ski that is called an unloader knee brace because it bends my knee bowlegged taking pressure off the lateral compartment of my left knee where I lack cartilage.

Unloader knee braces are also not well-proven in science.

You may have to get an MRI before you can get into a doctor to get PRP injections and the doctor you see (orthopedic surgeon) will also most likely take an x-ray of your knees.

All info below from Johns Hopkins University

Platelet-rich plasma consists of two elements: plasma, or the liquid portion of blood, and platelets, a type of blood cell that plays an important role in healing throughout the body. Platelets are well-known for their clotting abilities, but they also contain growth factors that can trigger cell reproduction and stimulate tissue regeneration or healing in the treated area. Platelet-rich plasma is simply blood that contains more platelets than normal.

To create platelet-rich plasma, clinicians take a blood sample from the patient and place it into a device called a centrifuge that rapidly spins the sample, separating out the other components of the blood from the platelets and concentrating them within the plasma.

After creating platelet-rich plasma from a patients blood sample, that solution is injected into the target area, such as an injured knee or a tendon. In some cases, the clinician may use ultrasound to guide the injection. The idea is to increase the concentration of specific bioproteins or hormones, called growth factors, in a specific area to accelerate the healing process.

The mechanism behind PRP injections is not completely understood. Studies show that the increased concentration of growth factors in platelet-rich plasma may stimulate or speed up the healing process, shortening healing time for injuries, decreasing pain, and even encouraging hair growth.

PRP injections are used for a range of conditions,* from musculoskeletal pain and injuries to cosmetic procedures.

Tendon, Ligament, Muscle and Joint Injuries

PRP injections may be able to treat a range of musculoskeletal injuries and conditions. For example, chronic tendon injuries such as tennis elbow or jumpers knee can often take a long time to heal, so adding PRP shots to a treatment regimen can help to stimulate the healing process, decrease pain, and enable a return to activities sooner.

Post-surgical Healing

Clinicians first used PRP to accelerate healing after jaw or plastic surgeries. Now, post-surgical PRP injections have expanded to help heal muscles, tendons, and ligaments, as procedures on these tissues have notoriously long recovery times.

Osteoarthritis

Early studies indicate that PRP injections may help treat osteoarthritis pain and stiffness by modulating the joint environment and reducing inflammation, but research is growing.

Hair Loss

PRP injections can be effective in treating male pattern baldness, both in preventing hair loss and promoting new hair growth. PRP can also aid in the stimulation of hair growth after hair transplants.

Skin Rejuvenation

PRP injections are sometimes used as an anti-aging treatment, but there is little evidence to show that PRP reduces wrinkles and other signs of aging.

PRP Therapy Risks and Side Effects

A PRP injection is a low-risk procedure and does not usually cause major side effects. The procedure involves a blood draw, so you should make sure you are hydrated and have eaten beforehand to prevent feeling lightheaded. After the procedure, you may experience some soreness and bruising at the injection site.

Because PRP injections are made up of your own cells and plasma, the risk of an allergic reaction is much lower than with other injectable medications like corticosteroids. Less common risks of PRP injections include:

If you are considering PRP injections, be sure to talk with your healthcare provider about all the benefits and risks.

View post:
Platelet-Rich Plasma Injections | What It's Like Getting PRP Injections Into The Knee as a Skier - SnowBrains

Healing of acute anterior cruciate ligament rupture on MRI and … – British Journal of Sports Medicine

Background

A common belief among researchers and clinicians is that a ruptured anterior cruciate ligament (ACL) has limited healing capacity. This belief has shaped current management strategies for ACL rupture. However, anatomical studies have demonstrated that the ACL has a rich vascular supply1 2 and histological studies describe ruptured ACLs passing though the typical phases of healing after injury, despite a slower rate of healing and reduced healing capacity compared with medial collateral ligament rupture.35 An absence of tissue bridging the gap between ligament remnants has been observed, which may inhibit healing of ACL rupture.6 The distance between the ACL origin to its insertion is shortest at 90135 of knee flexion.7 We have developed the novel Cross Bracing Protocol (CBP) that aims to reduce the gap distance between the ligament remnants by immobilising the knee at 90 of flexion for 4 weeks after acute ACL rupture in attempt to facilitate bridging of tissue and healing between the ruptured ACL remnants. After 4 weeks, knee range-of-motion is increased at weekly increments and the CBP is coupled with physiotherapist-supervised rehabilitation targeting lower limb neuromuscular control, muscle strengthening and power, and functional training to enable return-to-sport and recreational activities.

A 2021 systematic review identified only six studies that evaluated ACL healing on MRI after ACL rupture.8 Studies were of low methodological quality and five studies included 50 participants.8 More recently, an analysis of the KANON Trial observed MRI evidence of ACL healing at a 2-year follow-up in 30% of participants who were randomised to initial rehabilitation and optional delayed ACL reconstruction (ACLR).9 Those with MRI evidence of ACL healing reported better 2-year knee function and quality of life (QOL), compared with participants with no MRI evidence of ACL healing, and participants managed with early or delayed ACLR.9 Many ACL injured people experience poor long-term outcomes, including sport and activity limitations, persistent pain, an early onset of osteoarthritis and poor long-term QOL.1013 Considering the suboptimal outcomes with current management strategies, and the potential for ACL healing to result in favourable outcomes, new strategies to preserve and heal the native ACL should be explored. The objective of this study was to investigate MRI evidence of ACL healing, patient-reported outcomes and knee laxity in the first 80 individuals with acute ACL rupture managed non-surgically with the CBP.

This case series investigates outcomes from 80 consecutive patients with acute ACL rupture who were managed with the CBP. Data were collected in the course of clinical practice, and all participants provided informed consent for their data to be included in this study.

Eighty patients between the ages of 10 years and 58 years (mean (SD): 26 years (10 years)), who presented to a private sport and exercise medicine physician in Sydney, Australia (TC), with MRI confirmed acute ACL rupture between March 2016 and September 2021, were managed with the CBP (figure 1). Twelve out of 80 patients were residing outside of Sydney or impacted by COVID-19 restrictions and underwent virtual specialist consultations (TC), supplemented by in-person management and assessment from an experienced sports and exercise physician and physiotherapists trained in the CBP.

Participant flow chart. ACL, anterior cruciate ligament; ACLR, anterior cruciate ligament reconstruction; CBP, Cross Bracing Protocol; DVT, deep vein thrombosis; MCL, medial collateral ligament.

Patients of all ages, were considered eligible for the CBP if they presented within 1 month of acute ACL rupture, confirmed on MRI (ie, an ACL OsteoArthritis Score (ACLOAS) grade 3 representing full discontinuity of the ACL). To be considered for the CBP, patients needed to be functionally independent and capable of managing a period of knee immobilisation. Patients were considered ineligible if they had clinical or MRI evidence of structural concomitant injuries that necessitated surgical intervention (eg, an unstable bucket-handle meniscal tear) or a history of deep vein thrombosis (DVT) or pulmonary embolism. After the 10th participant, DVT screening was added to the eligibility criteria, whereby all patients underwent Doppler ultrasound to exclude DVT. The flow of participants through the study, including reasons for not offering the CBP and reasons for choosing ACLR (no participants chose rehabilitation alone), is presented in figure 1.

Patients were informed about treatment options: early ACLR, non-operative rehabilitation with optional delayed ACLR or trialling the CBP. Patients received information on the rationale and theoretical justification for the CBP, and they were aware that this was an experimental treatment with a chance of failure and possible need for ACLR in the future. The decision to trial the CBP was based on patient preference.

The CBP and accompanying rehabilitation protocol is described in online supplemental appendix 1. In patients presenting in the first week post-injury, the use of cryotherapy and anti-inflammatory medications was discouraged to minimise impairment of the acute inflammatory response.5 14 Paracetamol was prescribed as needed for pain. Fourteen patients who presented 7 days post-injury with minimal or no hemarthrosis/effusion underwent a platelet-rich plasma injection.

The injured knee was then secured at 90 flexion in a standard limited range-of-motion brace as early as convenient following injury (range: 031 days post-injury, median (IQR): 5 days (411 days)), by a physiotherapist trained in the CBP. Patients were advised to keep the knee fixed in the brace at all times for the first 4 weeks, including during sleep and showering. Patients were educated regarding safe use of crutches during the first 8 weeks (and use of additional mobility aids if desired, such as a knee scooter, i-Walker or wheelchair), while unable to sufficiently extend the knee to walk unaided. Patients were given advice regarding self-care, comfort and DVT risk mitigation strategies, including hydration and calf pump exercises. Prophylactic Clexane injections were introduced after the 10th patient. From patient 20 onwards, Rivaroxiban 10 mg was prescribed (for the first 8 weeks of the CBP) instead of Clexane.

After 4 weeks, the range-of-motion brace was adjusted at regular increments to allow progressive increases in range-of-motion (see online supplemental appendix 1). At week 10, unrestricted range-of-motion was allowed, and the brace was removed at 12 weeks. Weight-bearing was encouraged within the available range and patients completed standardised goal-oriented exercise-based rehabilitation while in the brace, and after brace removal until the point of return-to-sport (online supplemental appendix 1). Patients had weekly physiotherapist consults to check/adjust the brace and progress exercise-based rehabilitation (online supplemental appendix 1). Return-to-sport was not recommended until 912 months post-injury, and was dependent on patient and clinical factors, including desire to return-to-sport, completion of required rehabilitation and passing functional return-to-sport criteria.15

The first 4 patients had the brace removed and their first follow-up assessment at 9 weeks. After this, a decision was made to extend the CBP from 9 weeks to 12 weeks to protect the ACL for longer and enable more accurate interpretation of the MRI at the time of brace removal. Additionally, two patients for personal reasons (work demands/to care for young children) removed the brace at the end of week 4 and week 6. Both patients were compliant with the CBP before brace removal and completed rehabilitation post brace removal.

Details of all outcomes, including measurement method, time of measurement and interpretation, are presented in table 1.

Outcome measurement and interpretation

Patients have been involved in the development and refinement of the CBP, and the authorship team includes a patient who was managed with the CBP (MD).

All patients with acute ACL rupture managed with the CBP prior to October 2021 participated in the study, including 31 (39%) females, people aged 1058 years at the time of injury, and both private (69%) and publicly (31%) funded patients. Although only 3 women are included in the authorship team, the lead researcher is a woman and we include authors from a variety of career stages and clinical disciplines.

All continuous variables were assessed for normality and mean (SD) or median (IQR) reported, as appropriate. Participant characteristics and outcomes are presented for all participants, and based on 3-month ACLOAS. Mann-Whitney U tests were used to compare continuous outcomes (Lysholm Scale and ACLQOL scores) and Pearsons 2 tests were used to compare categorical outcomes (Lachmans test, Pivot-shift test and return-to-sport) between groups with lower versus higher ACLOAS grades on 3-month MRI (ACLOAS grades 01 vs ACLOAS grades 23). Since seven participants completed the Lysholm Scale and ACLQOL score after ACL re-rupture, a subgroup analysis was performed to present data and compare groups after excluding these seven individuals from the analysis (online supplemental appendix 2). For the two participants with missing MRI data at 3-month follow-up (decided not to undergo MRI), the ACLOAS from 6-month MRI was used to classify 3-month ACLOAS for analysis (95% of participants had the same ACLOAS at 3 months and 6 months, only 1 participant had a worse ACLOAS grade due to re-injury). Six people were missing 6-month MRI data (due to ACL re-rupture (n=3), pregnancy (n=1) or decided not to undergo MRI (n=2)). Since only one participant had missing data for the Lysholm Scale and ACLQOL scores, a complete case analysis was performed.

All individuals managed with the CBP provided consent for their data to be included in this study. Participants were aged a mean (SD) 26 (10) years at injury, 39% were female and 49% had concomitant meniscal injury (38 stable vertical tears in posterior horn of medial and/or lateral meniscus and 1 displaced medial meniscus ramp lesion). Participant characteristics are reported in table 2 for all participants and by ACLOAS grade on 3-month MRI (grade 1 vs grades 23). Participant characteristics are presented separately for participants with an ACLOAS grades 2 and 3, in online supplemental appendix 3.

Participant characteristics

At 3-month follow-up, n=72 (90%) had a continuous ACL (n=40 (50%) ACLOAS grade 1, n=32 (40%) ACLOAS grade 2). Of the 8 patients with ACLOAS grade 3 on 3-month MRI, 6 ACLs had attached to the lateral wall (n=3) or lateral wall and posterior cruciate ligament (n=3). Between 3-month and 6-month MRI, 4 participants changed from ACLOAS grade 1 to grade 0 and 1 participant changed from ACLOAS grade 2 to grade 3 due to subsequent knee injury. ACLOAS grades from 3-month and 6-month MRIs (complete case analysis) are presented in online supplemental appendix 4. Other participants sustained the same ACLOAS grade at 3 months and 6 months. MRI examples of ACL healing for five participants are presented in figure 2.

MRI images demonstrating MRI evidence of ACL healing for five participants. ACL, anterior cruciate ligament; ACLOAS, Anterior Cruciate Ligament OsteoArthritis Score.

Participants with an ACLOAS grade 1 on 3 month MRI reported better patient-reported outcomes on the Lysholm Scale and ACLQOL (including all ACLQOL subscales) compared with participants with an ACLOAS grades 23 (table 3). Online supplemental appendix 2 presents outcomes separately for participants with an ACLOAS grades 2 and 3. Online supplemental appendix 5 depicts participant scores based on time post-injury and 3-month healing status. Participants with an ACLOAS grade 1 had reduced knee laxity and a higher proportion returned to pre-injury sport (92% vs 62%) compared with participants with an ACLOAS grades 23 (table 3).

Participant outcomes

Eleven (14%) participants re-injured their ACL (mean (SD): 10 months (4 months), range: 518 months), 4 had ACLOAS grade 1, and 7 had ACLOAS grade 2 on 3-month MRI. After re-injury, 9 of 11 participants underwent ACLR (mean: 2 months after re-injury, range: 06 months), 1 participant decided to undergo the CBP again (resulting in evidence of ACL healing on MRI, ACLOAS grade 1). Mechanisms of re-injury included AFL/rugby (n=3), basketball (n=1), skiing (n=1), cycling accident (n=1), netball (n=1), Oz-tag (n=1), wrestling (n=1), dancing (n=1) and climbing (n=1). The four participants who re-injured their ACL despite ACLOAS grade 1 on 3-month MRI, did so during high-speed skiing/cycling accidents (5 months and 18 months post-injury), rugby (contact injury 10 months post-injury) and AFL (contact injury 17 months post-injury).

Two of 80 (2.5%) participants underwent an arthroscopic knee surgery, one participant for cyclops lesion removal 7 months post-injury and another underwent a partial lateral meniscectomy 5 months post-injury. Thirty eight of 39 (97%) meniscal tears were asymptomatic following the CBP, including one displaced medial meniscus ramp lesion.

Two patients were diagnosed with a below knee DVT (before DVT prophylaxis was added to the protocol), which were identified in the second week of the CBP, and were successfully managed with therapeutic dosing of Clexane. Both patients completed the CBP. Follow-up Doppler ultrasound demonstrated complete resolution of the DVT for both patients. Thereafter (11th patient onwards), DVT risk mitigation strategies were deployed as described in the Methods section.

Most patients reported mild and transient discomfort while adapting to the brace during the first week, often citing an awkward or uncomfortable sleeping position with the knee fixed at 90. This discomfort resolved for all patients without intervention. No patients opted to exit the programme due to discomfort or complication. At the time of unrestricted knee flexion in the brace, a flexion contracture (typically 515) was observed in 11 patients (14%). This resolved in all patients with physiotherapy exercises within 3 weeks. Contralateral lower limb overuse injuries, including pes anserine bursitis (n=1), insertional hamstrings tendinopathy (n=1) and patellofemoral pain (n=3), were observed at the time of brace removal.

This case series found that 72 out of 80 (90%) people with acute ACL rupture who were managed with a novel bracing protocol involving immobilisation of the knee at 90 flexion, had evidence of ACL healing (a continuous ACL) on 3-month MRI. An ACLOAS grade 1 on 3-month MRI was associated with better 12-month knee function and QOL, reduced passive knee laxity and a higher rate of return-to-sport, compared with an ACLOAS grades 23.

A recent analysis of the KANON trial found that 16 of 54 (30%) participants randomised to initial rehabilitation and optional delayed ACLR had signs of ACL healing on a 2-year MRI.9 Of the 30 participants who were managed with rehabilitation alone, 53% had MRI evidence of ACL healing at 2 years.9 In comparison, applying the same criteria we observed ACL healing in 72 of 80 (90%) participants on 3-month MRI. Six of 8 ACLs with discontinuous fibres had attached to the lateral wallposterior cruciate ligament. Although we graded these as discontinuous, it is possible that attachment to these structures could provide some function/stability, and it is not clear how this compares to the function/stability of an ACL graft. The high rate of healing observed on 3-month MRI suggests that the CBP could be conducive to ACL healing. To explore this potential, further research, including mechanistic studies, is required. Interestingly, patients had a range of concomitant injuries at baseline which became asymptomatic after the CBP. Only 1 of 39 patients with concomitant meniscal injuries had persistent symptoms after the CBP and underwent meniscal surgery. It is possible that the CBP could be beneficial for healing of concomitant injuries, this warrants further research.

Additionally, 37 of 40 participants (93%) with an ACLOAS grades 23 on 3-month MRI had an ACL rupture with a partial femoral avulsion, compared with only 7 (18%) participants with an ACLOAS grade 1. Although outside the scope of this study, it is possible that characteristics of ACL rupture observed on acute MRI (including partial/complete femoral avulsion, the displacement of ACL tissues outside of the intercondylar notch and gap distance between the ruptured ACL stumps) are associated with the likelihood of ACL healing. Further studies are needed to explore this possibility, with potential to inform ACL injury management decisions.

The favourable outcomes observed in patients with signs of ACL healing in our study are supported by findings from the KANON trial. In the KANON trial, participants with an ACLOAS of 02 on a 2-year MRI reported better knee function and QOL compared with participants with ACL discontinuity, and people who had delayed or early ACLR.9 Notably, only 8 (10%) patients in our study had ACL discontinuity on a 3-month MRI, and we used a different cut-off when comparing outcomes between groups. Collectively, results from the KANON trial and CBP suggest there may be a spectrum of ACL healing, whereby a more normal MRI appearance of the ACL may be associated with favourable patient outcomes.

Surprisingly, patients with an ACLOAS grades 23 reported excellent Lysholm Scale scores on average, even though scores were lower than patients with an ACLOAS grade 1. A Lysholm median score of 98 reported by people with an ACLOAS grade 1 is better than mean scores reported 2471 months after ACLR using autograft (mean scores range from 85 to 95).16 In contrast, the difference in ACLQOL scores was large between people with lower and higher grades of ACL healing. People with an ACLOAS grade 1 reported a median (IQR) ACLQOL score of 89 (7696). In comparison, people managed with ACLR or rehabilitation alone, report mean ACLQOL scores in the range of 5076, across a variety of time-points after ACL injury.17 The ACLQOL scores reported by people with an ACLOAS grades 23 may be more comparable with ACLQOL scores reported after ACLR and management with rehabilitation alone.17 Examining the ACLQOL domain scores suggests the greatest differences were within the recreational and sport participation, lifestyle and social emotional domains, with smaller differences observed in the symptoms and physical complaints and work-related concern domains.

The lower proportion who returned to sport with an ACLOAS grades 23 (64%) compared with an ACLOAS grade 1 (92%) could partly explain the lower QOL in this group considering return-to-sport is a key determinant of QOL after ACL injury.18 These return-to-sport rates are high compared with studies in ACL reconstructed individuals, where a pooled average of 55% of non-professional athletes returned to sport after ACLR.10 It should also be noted that patients in our study were aware of the degree of healing observed on MRI. It is possible that patients who received feedback that they had a suboptimal healing result on MRI had lower knee confidence and negative mental impacts compared with patients who received more positive feedback. This could also contribute to lower QOL scores in these domains.

It is not known whether a continuous ACL observed on MRI reflects restoration of pre-injury ACL function. Although, the high self-reported knee function and return-to-sport rate in people with an ACLOAS grade 1 suggests a positive association with knee function. It is important to note that 11 patients (14%) had re-ruptured their ACL at the time of follow-up. The 4 patients who re-injured their ACL despite an ACLOAS grade 1 on a 3-month MRI did so during competitive sport (rugby/AFL contact injuries) or high-speed skiing/cycling accidents. It is not clear whether re-injury of the ACL is a reflection of reduced tensile strength of the ACL fibres, considering the mechanisms of re-injury were similar to the mechanisms of initial ACL rupture. The rate of re-injury observed in our study may be comparable with re-injury rates following ACLR, whereby approximately 1-in-5 young athletes suffer a rupture of the ACL graft or contralateral ACL, and around 90% of these injuries occur after return to high-risk sports.19 Interestingly, one patient elected to undergo the CBP after re-rupturing their ACL and achieved an ACLOAS grade 1 on a 3-month MRI and returned to sport (rugby), after re-completion of the CBP. Longer-term follow-up is required to gain greater understanding of survivorship of the healed ACL and the risk of subsequent knee injury following management with the CBP.

In view of the promising outcomes of this case series and the potential advantages of preserving the native ACL following injury, further research in this area is warranted. Prognostic studies are needed to determine whether certain presentations are less likely to heal when managed with the CBP. In the future, the potential for the ACL to heal may be an important consideration when deciding on surgical or non-surgical management. We found that signs of ACL healing were apparent on MRI as early as 3 months after ACL rupture. Three months is the typical duration that people trial initial rehabilitation before considering delayed ACLR. It is possible that 3-month MRI findings could identify patients who would benefit from ACLR. Only 10% of patients with an ACLOAS grade 1 at 3 months had progressed to an ACLOAS grade 0 at 6 months. Further research is needed to understand the timeline and stages of ACL healing. Additionally, clinical trials are needed to compare outcomes for patients managed with the CBP, compared with those who are managed with ACLR or rehabilitation alone. Of particular importance will be the investigation of re-injury rates, return-to-sport, patient-reported outcomes, functional stability and the prevalence of knee osteoarthritis.

Bridge enhanced ACL repair (BEAR) is a surgical technique that augments repair of the ligament with a scaffold implant (a resorbable protein-based implant containing autologous blood) positioned between the torn ends of a midsubstance ACL tear in attempt to facilitate healing.20 An interesting area for future research is the comparison of ACL healing on MRI and clinical outcomes following management with BEAR compared with the CBP. Additionally, there may be specific ACL rupture presentations that benefit from early surgical intervention to assist with facilitating ACL healing. For example, acute ACL injuries with a large gap distance between torn remnants and acute ACL injuries with displaced ACL tissue outside the intercondylar notch might benefit from surgery to reduce and realign the ACL tissues. There could also be a role for bracing in knee flexion postoperatively to protect the repair and/or reduction of the injured ACL tissues (akin to management of displaced bone fractures with open reduction internal fixation followed by a period of postoperative immobilisation). Further research is needed to explore this potential.

This was a pragmatic study, whereby data were collected in the course of clinical practice rather than in a research setting. For this reason, some adaptations were made to the CBP overtime. Our study design did not allow comparison of outcomes with people managed with ACLR or rehabilitation alone. There is also potential for selection bias. After the 50th patient was braced, patients were discouraged from undertaking the CBP if they had a femoral avulsion and/or ACL tissue displaced outside the boundaries of the intercondylar notch. Although 14 of 29 patients underwent the CBP despite this advice, 15 of these individuals chose ACLR. The overall proportion with an ACLOAS grade 1 at 3 months may have been lower if these 15 individuals had not received this advice and underwent the CBP. Tests of passive knee laxity were performed by two unblinded physicians and may be subject to detection and observer bias, a clinical trial, including blinding of examiners, is needed. Further studies may also benefit from using a knee arthrometer to collect more objective measures of knee laxity. MRIs were graded by three radiologists who were aware that patients had undertaken the CBP. Although this case series highlights the potential for positive outcomes using the CBP, larger cohorts with longer-term follow-up and, in particular, randomised clinical trials are needed.

Read the original:
Healing of acute anterior cruciate ligament rupture on MRI and ... - British Journal of Sports Medicine

Princeton hangs on to hand 1st loss of season to Duquesne – TribLIVE

By now, its no secret Duquesnes basketball schedule was assembled with postseason aspirations in mind.

Not the College Basketball Invitational, where the Dukes made an appearance last season, mind you. Not even the National Invitation Tournament.

Were building this to get to the (Atlantic 10 Tournament) championship and to get to the (NCAA) Tournament, sophomore point guard Kareem Rozier said.

Its a hard schedule, coach Keith Dambrot said, reflecting on Duquesnes 70-67 loss to Princeton on Wednesday night. We felt like we were going to have a relatively good team, so why not?

Its results such as the Dukes first loss of the season that Rozier and his teammates are hoping, come March, will shape the Dukes into a Tournament-type team for the first time in nearly five decades.

I truly believe this is the team that will do it this year, Rozier said. But to do it, youve got to go through some rough patches, and this is one of them.

Duquesne and Princeton waited until the last second to settle their outcome before the Tigers edged the Dukes and sent a boisterous UPMC Cooper Fieldhouse crowd home disappointed.

Matt Allocco scored 23 points on 10-of-13 shooting and Princeton (3-0) withstood Duquesnes last-second rush to remain undefeated.

Duquesne trailed 68-67 with a chance to come away with a win in the closing seconds, but Fousseyni Drames contested layup clanged off the rim and Rozier fouled Princetons Xaiavian Lee with four-tenths of a second remaining.

Lee converted both free throws to seal the victory for Princeton.

Lee added 20 points and Blake Peters contributed 11 for The Tigers, who led Duquesne for nearly the entire game, trailing for just 46 seconds in the first half.

A classic giant slayer the Tigers last season reached the Sweet 16 as a No. 15 seed Princeton shot 56.5%.

The Tigers carried an impressive NCAA Evaluation Tool ranking of 93 following victories over Rutgers (NET ranking of 40) and Hofstra (85).

We had our shot tonight and it didnt fall in our favor, Rozier said. It wasnt our time, and thats OK. It hurts right now. Princeton would have been a great win.

Duquesne, with a NET ranking of 137, opened the season with impressive victories over Cleveland State (185) and College of Charleston (52). And theres more to come before the A-10 opener Jan. 3 at Massachusetts.

The Dukes will face Nebraska (92) next week and four other opponents later on with impressive NET rankings: Bradley (78), Marshall (83), Santa Clara (87) and UC Irvine (102).

On Tuesday, UC Irvine and Santa Clara knocked off Power 5 conference teams, the Anteaters upsetting No. 16 Southern California and the Broncos defeating Stanford.

We have enough guys, Dambrot said.

But two big men that Dambrot has been counting on Dusan Mahorcic and Tre Williams are sidelined indefinitely by injuries.

Mahorcic, a 6-foot-10, 235-pound transfer from North Carolina State, has yet to play while working his way back from a serious knee injury. During a pregame interview on SportsNet Pittsburgh and ESPN Plus, Mahorcic said he was expecting to receive two additional Platelet-rich plasma injections and hoped to make his Duquesne debut in a month to six weeks.

The 6-7, 250-pound Williams, who sustained a hand injury on Friday against Charleston, is due back sooner than later, unless he has a complication, Dambrot said.

Until then, Duquesne will survive, he said.

But the Dukes ran into trouble Wednesday, though Dambrot quipped, If we make (the last shot), were all happy.

Jimmy Clark III led Duquesne (3-1) with 17 points. Dae Dae Grant added 16 for the Dukes, who return to UPMC Cooper Fieldhouse on Friday against Rider in a continuation of the Cornhusker Classic. The Dukes defeated Stony Brook on Monday in the first round.

Duquesne trailed at halftime for the third time in its first four games, but it couldve been by a wider margin had former Our Lady of Sacred Heart star Jake DiMichele, inserted late in the first half, not hit a 3-point shot at the buzzer for his first college points to cut the Princeton lead to 37-31.

A Grant 3-pointer pulled Duquesne within 52-49, and he nearly tied the score on the next possession, but his long attempt from the behind the arc bounded off the back of the iron and out of bounds.

Princeton then scored six unanswered points to go up 58-49.

Clark, who went to the bench briefly with his fourth foul at the 11:02 mark, returned and promptly swished a 3-pointer to cut the Princeton lead to 58-54.

A pair of Rozier free throws with 4:34 left kept Duquesne close at 63-60 and the Dukes defense then trapped Princeton into calling a timeout before the Tigers could escape.

Princeton lost possession and Drame scored on a driving layup to pull Duquesne within 63-62, igniting a crowd infused with an unusually rowdy Dukes student section.

Zach Martinis three-point play gave Princeton some breathing room again at 66-62 before Duquesne responded when Clark scored on a driving layup and was fouled. He converted the free throw to again pull Duquesne within a point, 66-65, with 1:45 left.

Alloccos acrobatic shot underneath for Princeton kept the the Tigers in control, but Grant hit a pair of free throws at the other end to make it 68-67.

The hectic early season schedule includes seven games in November for Duquesne, which appeared a step slow, at times, against Princetons methodic approach.

Its a tough team to play at the beginning of the year, Dambrot said. It was a tough game. Our guys battled to the end. Our guys are gutty guys. They played hard. They didnt quite have it, but they hung around and hung around and gave ourselves a good chance to win.

Looking relaxed, despite his teams first loss, Dambrot stood up, forced a weak smile and said, See ya next See ya in 24 hours.

Dave Mackall is a Tribune-Review contributing writer.

Read more:
Princeton hangs on to hand 1st loss of season to Duquesne - TribLIVE

Platelet-Rich Plasma Market Is Anticipated To Increase At A Steady CAGR of 12% by 2031 | Fact.MR – Yahoo Finance

FACT.MR

Fact.MRs latest report on platelet rich plasma market analyzes opportunities, trends, and threats affecting growth in the market. It offers an in-depth analysis of the market in terms of product type, application, and end users. The study also reveals interesting information about strategies adopted by market leaders.

Rockville , April 11, 2023 (GLOBE NEWSWIRE) -- The global platelet-rich plasma market reached US$ 400 million in 2020. From 2021 to 2031, global platelet-rich plasma demand will thrive at 12% CAGR. Total market valuation at the end of 2031 is likely to reach US$ 1.5 billion.

Increasing prevalence of sports injuries incidence and chronic orthopedic conditions is a key factor driving the platelet-rich plasma market. Similarly, rising number of cosmetic and surgical procedures performed globally will elevate demand.

A concentrate of platelet-rich plasma protein obtained from whole blood is called platelet-rich plasma or PRP. It is also referred to as autologous conditioned plasma. It contains different growth factors and cytokines that can trigger healing of joints and soft tissues.

For Critical Insights on this Market, Get A Free Sample Report:https://www.factmr.com/connectus/sample?flag=S&rep_id=170

In recent years there has been a significant increase in the demand for platelet-rich plasma. This is due to its use in applications such as tissue regeneration, scar revision, wound healing, alopecia, etc. PRP is also showing promising results in the treatment of conditions such as osteoarthritis.

Hence, increasing cases of sports injuries, orthopedic diseases, and musculoskeletal disorders will fuel PRP demand through 2031. For regenerative medicine, PRP is a significant source of personalized products for each patient that support wound healing and the repair cascade.

PRP has become a magical potion for flawless skin and hair. It is gaining immense traction in cosmetic surgery and hair loss treatments. PRP injections are being increasingly used to treat hair loss conditions such as alopecia.

Story continues

In 2020, PRP use in cosmetics increased by around 25% over the past four years, according to the American College of Plastic Surgeons report. Rising usage in cosmetics will therefore continue to boost PRP sales revenues through 2031.

Several studies are presently being conducted to assess the effectiveness of PRP in therapeutic areas such as disc herniation and hair loss. It is believed that PRP therapy can rejuvenate skin and reduce wrinkles.

Although this therapy cannot replace certain critical conventional treatments, it can reduce the economic cost of standard medical procedures.

In hair transplantation, PRP binds to growth factors and increases the proliferation of human dermal papilla cells, resulting in hair follicle formation and maintenance.

Platelet-rich plasma has also gained wider popularity in plastic surgery. Properties such as ease of use, inexpensive manufacturing using patient cells, and little or no risk of side effects are the main reasons for the increasing adoption of PRP in therapy.

Based on product type, pure platelet-rich plasma kits segment dominates the global market. This is due to various advantages of pure-PRP kits which include enhanced wound healing and tissue repair.

Regionally, North America will continue to lead the global PRP market. This is due to increasing cases of sports injuries and orthopedic disorders. Similarly, development of PRP-based therapies, rising interest in personalized medicine, and high sourcing from end-users such as hospitals and clinics will boost North America market.

Key Takeaways from the Market Report:

Global platelet-rich plasma sales revenue will increase at 12% CAGR during the forecast period.

Based on product type, pure platelet-rich plasma kits segment held around 50% revenue share in 2020.

Based on end user, hospitals segment is set to thrive at 10% through 2031.

India platelet-rich plasma market will exhibit a CAGR of 8% from 2021 to 2031.

In the United Kingdom, platelet-rich plasma demand is likely to surge at 8% CAGR.

The United States market will experience a 9% CAGR throughout the projection period.

Growth Drivers:

The rising incidence of orthopedic and sports injuries coupled with increasing acceptance of PRP as an effective treatment option will drive the market.

Rise in surgical and cosmetic procedures will generate high demand for PRP treatments.

Increasing awareness about PRP and its potential advantages will boost sales revenue

Technological advancements in the PRP devices supported by new product launches will foster market development

Growing popularity of plasma-rich protein therapies for treating various conditions will create new growth prospects

Restraints:

High cost of PRP procedures and various side effects associated with PRPs are limiting market expansion.

Low awareness about PRP in several regions of the world might restrain market development.

Get Customization on this Report for Specific Research Solutions:https://www.factmr.com/connectus/sample?flag=RC&rep_id=170

Competitive Landscape:

Key players are focusing on implementing various strategies to expand their product offerings and strengthen their geographic footprints. They are spending large amounts on research and development.

For instance,

In February 2020, all assets of Cellmedix Holdings LLC which includes the Centrepid Platelet Concentration System were acquired by EmCyteCo. This expanded the business's product portfolio.

In September 2021, Royal Biologics Maxx-PRP Concentration System received FDA 510K approval.

Key Companies Profiled by Fact. MR

Arthrex, Inc.

Johnson & Johnson

Zimmer Biomet Holdings, Inc.

Exactexh, Inc.

Stryker Corporation

Terumo Medical Corporation

Biotest Aktiengesellschaft

CSL Ltd.

More Valuable Insights on Platelet-Rich Plasma Market

In the report, significant growth approaches such as acquisitions and mergers, cooperation, and partnerships are operated. The reports provide an in-depth report of the opportunities and growth drivers anticipated to boost the expansion of the platelet-rich plasma market through segmentation as follows:

Product Type:

Platelet-Rich Plasma Instruments

Pure Platelet-Rich Plasma Kits

Leucocyte- Rich Platelet-Rich Plasma Kits

Platelet-Rich Fibrin Kits

Pure Platelet-Rich Fibrin Kits

Application:

Orthopedic Surgery

Cosmetic Surgery

General Surgery

Neurosurgery

Other Surgeries

End User:

Hospitals

Orthopedic Clinics

Dermatology Clinics

Others

Region:

North America

Latin America

Europe

South Asia

East Asia

Oceania

Middle East & Africa

Buythis Premium Research Report (170Pages, 241 Tables & 87 Figures)https://www.factmr.com/checkout/170

Key Questions Covered in the Platelet-Rich Plasma Market Report

What will be the demand outlook for the platelet-rich plasma market during the forecast period?

Which are the challenges faced in the platelet-rich plasma market?

Which application will lead the growth in the platelet-rich plasma market from 2021 to 2031?

What is the projected market valuation of the platelet-rich plasma market in 2031?

Which are the factors driving the platelet-rich plasma market from 2021 to 2031?

Which end user will generate maximum revenue in the platelet-rich plasma market?

Explore Fact. Mrs Coverage in the Healthcare Domain

Plasma Fractionation Market: The global plasma fractionation market is set to reach a valuation of US$ 65 billion by 2032. Total demand for plasma fractionation will rise at 7.3% CAGR over the next ten years. Rising prevalence of chronic disease and widening usage of immunoglobulins for treating several conditions are driving the market forward.

Plasmapheresis Market: As per Fact.MR, global demand for plasmapheresis is set to increase at 7.4% CAGR through 2032. Total market valuation at the end of 2032 will reach US$ 2.6 billion. Increasing incidence of autoimmune diseases and growing health awareness are key factors driving the plasmapheresis market.

Mycoplasma Detection Systems Market: The global mycoplasma detection systems market size reached US$ 560 million in 2021. Over the next ten years, global mycoplasma detection systems sales will surge at 9.6% CAGR. By the end of 2032, the total market valuation will cross US$ 1.5 billion. Rising emphasis on mycoplasma testing by research and pharmaceutical companies will elevate mycoplasma detection system demand.

About Fact.MR

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our clients satisfaction.

Contact:US Sales Office11140Rockville PikeSuite 400Rockville, MD20852United StatesTel: +1 (628) 251-1583, +353-1-4434-232 (D)Connect to Author: Mr. Shambhu Nath JhaEmail:shambhu@factmr.com Sales Team:sales@factmr.comFollow Us:LinkedIn|Twitter|YouTube

Read the original here:
Platelet-Rich Plasma Market Is Anticipated To Increase At A Steady CAGR of 12% by 2031 | Fact.MR - Yahoo Finance

When Blood Is a New Alternative Medicine for Pain Relief at Chula … – PR Newswire

BANGKOK, April 11, 2023 /PRNewswire/ --Chula Medicine researchers have successfully published an article on the injection of patient's own platelets rich plasma into the shoulder ligaments resulting in painreduction, heal torn ligaments and restore torn muscles as an alternative to surgery while reducing the side effects of prolonged use of pain medications.

"Pain"is a condition that no one wishes to experience. And when it occurs, people want to heal as soon as possible. This can be achieved through taking painkillers or alternative medical approaches such as acupuncture, massage, using heat compression, etc. But today,Chula Pain Clinic, King Chulalongkorn Memorial Hospital, The Thai Red Cross Society has a new proven treatment for pain derived from the person's own "platelets" to offer.

"Platelet-Rich Plasma (PRP) injectionfor shoulder ligament injuries or "rotator cuff tears" is one of the treatments we have been doing for over 5 years." ExplainsAssistant Professor Marvin Thepsoparn, MD, an anesthesiologist and pain management specialist at the Pain Clinic, King Chulalongkorn Memorial Hospital, The Thai Red Cross Society. "This approach helps to reduce the side effects of painkillers and is very safe because the patient's own platelets and plasma are used to inject back into patient's injury site to stimulate self-repair," Dr. Thepsoparn is discussing how to relieve pain with platelets.

This research was conducted in collaboration with the Orthopaedic Sports Unit of King Chulalongkorn Memorial Hospital to study pain care for people who have suffered injuries from work, sports, and abnormal body movements. These are the causes of muscle injuries and torn ligaments, which can lead to lifelongchronic pain.

"In this study, we compared the efficiency of treatments by performing an MRI of the shoulder of patients who had already received platelet injection for 6 months, and those who did not use this method to treat torn shoulder ligaments. We found that injecting of the concentration of platelets into the shoulder ligaments significantly reduced pain within 1 2 months and also helped repair the tear, resulting in better healing of the ligaments and a reduction in size of the tear. As a result, patients did not have to suffer from chronic pain, avoided surgery, and eliminate the risk of continuously taking painkillers for an extended period."

The concentration of platelets a new option for pain relief

Dr. Marvin explains the two commonnon surgicalapproaches to pain treatment today: medication and non-drug treatment.

1. Pain treatment with standard analgesic drugs that are commonly used include:

2. Pain Management without medication can be divided into two groups:pain intervention procedures such as radiofrequency ablation of nerves, steroid injection and PRP injection. Secondly, physical therapy by Rehabilitation Medicine which can be done in various ways, including shock wave therapy, ultrasound therapy, warm compress, massage, cold compress, acupuncture and music therapy, etc.

"PRP Injection for body regeneration is considered an alternative medicine that has been practiced abroad for over 10 years. Platelets have various substances that the body produces for self-repair. Therefore, platelet injection has been studied both for cosmetics purposes and for pain management in the knees, shoulders, and other organs in the body," explained Dr. Marvin. He added that many hospitals in Thailand now use this approach as an anti-aging medicine.

Blood quality: efficiency for pain relief

Because this method uses the patient's own platelets, the effectiveness of treatment varies depending on the patient's physical condition, age, lifestyle, habits, andblood quality of the individual patient.

"If the patient is strong, exercises enough, or is an athlete, the blood quality will be good, and so is the body repair effect."

Dr. Marvin cited a foreign study of platelet injections which indicated that the effectiveness of platelet injections in body repair would be very effective for patients under the age of 55.

"This method is very safe because it uses the patient's own blood for treatment, so there are no side effects like using conventional painkillers. Often, patients over 60 years old come to seek treatment using this method, and the doctor agreed to do it, but informs the patient that the effects may not be as good as those who are under 55 years old."

"The treatment is done by taking about 15-30 ml of venous blood and then running it through a centrifuge to concentrate the platelets and splitting the plasma and red blood cells. Then take the plasma with platelets to be used for immediate treatment."

Who is PRP not suitable for?

Though very effective, PRP injection is not suitable for all patients, especially the following two groups:

Shoulder ligament problems trending ailments in urbanites

Until recently,Chula Pain Clinichas taken care of many patients suffering from chronic pain caused by shoulder ligament problems.

"We found that shoulder ligament problems are mostly the result of heavy lifting, work related injuries, and sports injuries. These injuries often take a long time to heal and recover from. PRP injections are therefore beneficial for athletes, office workers, and anyone wanting to recover from injuries in a shorter time so that they can get back to work, compete in sports and live a high-quality life as soon as possible," explained Dr. Marvin briefly.

"We atChula Pain Clinichave a comprehensive approach to patient care, where doctors including surgeons, orthopedic specialists in shoulder surgery, and rehabilitation doctors work together to restore the shoulder function." Dr. Marvin explained

"The doctors begin by selecting the appropriate treatment for the best results that can improve the patients' quality of life. If an ultrasound or MRI shows shoulder ligament injury or frozen shoulder and the team diagnoses that surgery is not required nor suitable, exercise would not help alleviated the pain, an PRP injections should be administered. The patient will be referred to receive PRP injections.Most Patients will receive one or at most two injections, and the pain should have expected to decrease by 80 percent. The remaining 20 percent of the pain will go away with time and rehabilitation exercises.

Dr. Marvin further added, "the cost of treatment is around 9,000 baht per session (procedure)."

The Future of Research on Pain Management with Patients' Own Blood

Dr. Marvin explained the progress of clinical research "in medicine, we do not stop researching to help relieve patients from pain and suffering. This research has also been extended to other organs, such asthe study of PRP injections to suppress pain in fused vertebrae (Ankylosing Spondylitis) cases. The study has reached the 50 percent progress milestone, and we are still looking for patients to participate in the study." Dr. Marvin invited those interested to make an appointment at the Chula Pain Clinic to be examined and diagnosed by physicians to see if they have Back pain and if eligible, patients can choose to participate in the study voluntarily, free of charge.

Stop the pain at the Chula Pain Clinic

"Nobody wants to be in pain, but when ill, they need to be healed. Would it be better if the patients don't need to suffer from pain which is a side effect of their long period of treatment and rehabilitation? This is the concept of the Pain Clinic," Dr. Marvin concluded.

Interested parties suffering from rotator cuff pain, or pain in other parts of the body can receive an examination for correct diagnostics and treatments atPain Clinic,17th floor, Phor Por Ror Building, King Chulalongkorn Memorial Hospital, The Thai Red Cross Society during Monday Friday from 8.00 a.m. 4.00 p.m. by making an appointment in advance or by calling +66 2256 5230.

Information Box

Open for volunteers to participate in pain management research project to improve quality of life

Chula Pain Clinic also has two other clinical research projects on pain management to develop better pain relief and pain management options for patients. We are accepting volunteers to participate in the projects, which require patients with physical pain as follows:

Individuals who are interested in taking part in the aforementioned study may request an appointment at Chula Pain Clinic to undergo a pain diagnosis for any disease. If deemed eligible, patients have the option to voluntarily participate in the study and receive treatment free of charged. Those interested in participating in the above study can request an appointment at theChula Pain Clinicfor a diagnosis of pain from any disease. If eligible, patients can choose to participate in the study voluntarily to receive treatment free of charge.

For the full release and more images, please visit: https://www.chula.ac.th/en/highlight/110448/

About Chulalongkorn University

Chulalongkorn University sets the standard as a university of innovations for society and is listed in the World's Top 100 Universities for Academic Reputation, in the Quacquarelli Symonds (QS)World University Rankings 2021-2022.

If you would like more information about this topic, please contact Miss Thanita Wangvanichapan at (+66) 2218 3280 or email [emailprotected]

SOURCE Chulalongkorn University

See original here:
When Blood Is a New Alternative Medicine for Pain Relief at Chula ... - PR Newswire

‘Brotox’ takes over TikTok: Why more men are getting cosmetic surgery – PR Week

Botox, which celebrated its20th anniversaryofFood and Drug Administrationapproval last year, is becoming increasingly popular among young men a trend dubbed as brotox.

The trend is perhaps unsurprising given Gen Z and millennials tendencies to focus on self-care,glow-ups and self-improvement.

The brotox boom is making waves among both young and old men and TikTok is home to various iterations of it.

Since brotox is having its moment in the sun, its worth looking into how popular cosmetic procedures are among men.

According to theAmerican Society of Plastic Surgeons(ASPS), cosmetic surgery and non-surgical aesthetic procedures among men rose by 29% between 2000 and 2018. In 2020 alone, more than 265,000 men got Botox procedures to target wrinkles in their face.

In particular, buttocks lifts and cheek implants saw the greatest increases among men between 2000 and 2020, rising 1,616% and 644%, respectively. Procedures including lip augmentations and laser skin resurfacing also became more popular during that time period,according to ASPS.

The trend has taken off partially due to the fact that negative connotations around Botox or cosmetic surgery for men have begun to dwindle, according toCynthia Elliott, owner and primary practitioner at cosmetic surgery clinicSkinspirations.

The stigma of vanity surrounding cosmetic procedures for men has evaporated, Elliott said in a statement. Minimally invasive treatments with little downtime and natural-looking results give men the same benefits women have enjoyed for decades enhanced self-esteem, confidence and sociability.

Indeed, a quick search on TikTok will unveil numerous men trying out Botox to treat fine lines and wrinkles giving a rundown on how the experience went for them.

Here are a few Brotox trends theyre trying out.

1. Getting rid of forehead wrinkles

Perhaps one of the most noticeable areas for wrinkles to appear is on the forehead either horizontally or within the glabellas (also known as the 11s between your eyebrows).

Before and after videosshow how a Botox treatment can minimize forehead creases, with men showcasing the differences for their followers.

2. PRP injections

In one recent video, TikTokerAndre Gadboisprovides a rundown of his recent cosmetic procedures including under-eye injections andnasolabial fold PRP injections. Gadbois explains that PRP injections involve using his own blood to extract platelet rich plasma, then injecting it back into the area of concern to stimulate healing and improved appearance.

While PRP injections have grown in popularity among cosmetic procedures, becoming a trending therapyaccording to the ASPS, the scientific evidence surrounding their efficacy for that purpose is still limited.

3. Crows feet

The peskycrows feetthat form in the corners of your eyes when you smile arent just an aesthetic concern for women.

Now, more men are seeking to minimize crows feet through Botox.

4. Lip flips

Lip flips have become increasingly popular as they offer a more subtle way of plumping your lips. The procedure involves injecting Botox into the upper lip to relax the muscles and make the lip flip upwards a little bit. Men are picking up the trend as well.

5. Eyelid lifts

Dilip Madnani, a plastic surgeon in New York with a TikTok following of more than 156,000, posted a video last year showing how his elderly father healed after getting upper eyelid surgery.

Eyelid lifts help to reduce the appearance of bags under the eyes, notesDr. Cat Plastic Surgery, in addition to removing excess skin from the upper eyelid. Not only does the removal of excess skin improve the field of vision, but it also creates a more youthful face and brighter eyes.

My dads upper eyelids surgery progress over the last 3 days. facelift, Plasticsurgery, drmadnani, FacialPlasticsurgery, Fillers, EyelidSurgery, NeckLift, fattransfer, ExpertInjector, NYC, LongIsland, blepharoplasty, eyebags, skincare, earlobe, minilift, localanesthesia, facesurgeon, #drmadnani #woodbury #centralpark beforeandafter, #newyork

6. Fillers, and more fillers

Men are realizing that its possible to get fillers for your nose rather than going through a fullrhinoplasty.

Whether your nose was damaged from an injury or you simply want to tweak how it looks, nose fillers and Botox are becoming increasingly common for men.

In one video, TikTokerxthuyledescribes how she managed to persuade her boyfriend to get filler and Botox on his nose after he got his nose broken at age 14.

Couples who get fillers together stay together, she says.

7. Botox for aging prevention

Anti-aging isnt just an area of concern for women; men want to appear youthful for as long as possible too.

More men are turning to Botox as a preventive measure to avoid forehead, frown and crows feet wrinkles. Boys get injectables too, the caption states.

This story first appeared on mmm-online.com.

Read the original here:
'Brotox' takes over TikTok: Why more men are getting cosmetic surgery - PR Week